Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective study of the influence of CYP3A4/CYP3A5 and MDR1 [multidrug resistance] gene single nucleotide polymorphisms on long-term tacrolimus disposition in renal allograft recipients: a five year follow-up study using abbreviated concentration-time measurements

Next Previous
Trial Profile

Prospective study of the influence of CYP3A4/CYP3A5 and MDR1 [multidrug resistance] gene single nucleotide polymorphisms on long-term tacrolimus disposition in renal allograft recipients: a five year follow-up study using abbreviated concentration-time measurements

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tacrolimus (Primary)
  • Indications Renal transplant rejection
  • Focus Pharmacogenomic; Pharmacokinetics

Most Recent Events

  • 03 Jan 2007 New trial record.
  • 15 Dec 2006 Biomarkers information updated

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top